Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461536 | 0.88 | KCNH2 (0.47) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5464106 | 0.83 | KCNH2 (0.46) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5470349 | 0.82 | KCNH2 (0.46) | KCNH2DRD2SIGMAR1DRD3LMNA | |
| SCHEMBL5457479 | 0.81 | ALDH1A1 (0.49) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5457442 | 0.81 | KCNH2 (0.63) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5463260 | 0.80 | GRIN2B (0.51) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5468561 | 0.78 | KCNH2 (0.64) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5464120 | 0.77 | KCNH2 (0.61) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5457660 | 0.77 | KCNH2 (0.59) | KCNH2GRIN2BOPRL1OPRM1OPRD1 | |
| SCHEMBL5457356 | 0.76 | KCNH2 (0.54) | KCNH2GRIN2BOPRL1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1673366-A1 | 1-\"2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL]-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035522-A1 | 1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | KCNH2 163/4885GRIN2B 7/4885OPRL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.